Bromocriptine is a medication that mimics dopamine in the brain, and it’s prescribed for several distinct conditions: high prolactin levels (hyperprolactinemia), prolactin-secreting pituitary tumors, Parkinson’s disease, acromegaly, and type 2 diabetes. Its versatility comes from the way it activates dopamine receptors throughout the body, producing different therapeutic effects depending on the dose and the target tissue.
How Bromocriptine Works
Bromocriptine activates D2 dopamine receptors while partially blocking D1 dopamine receptors. This selectivity matters because D2 receptors control prolactin release from the pituitary gland, regulate movement-related brain circuits, and influence metabolic signaling in the hypothalamus. By stimulating these receptors, bromocriptine essentially fills in for dopamine wherever the body isn’t producing enough of it, or where extra dopamine activity provides a therapeutic benefit.
High Prolactin Levels and Pituitary Tumors
The most established use of bromocriptine is treating hyperprolactinemia, a condition where the pituitary gland produces too much prolactin. Excess prolactin can cause irregular or absent periods, unwanted breast milk production (galactorrhea), infertility, and reduced sex drive. In men, it can lower testosterone and cause sexual dysfunction. Bromocriptine directly suppresses prolactin release from the pituitary by activating dopamine receptors on the cells that produce it.
For prolactin-secreting pituitary tumors (prolactinomas), bromocriptine both lowers prolactin levels and can shrink the tumor itself. Treatment typically starts at 1.25 to 2.5 mg once daily, with gradual increases every few days as tolerated. Most people end up on doses below 15 mg per day. The effects on prolactin levels are usually noticeable within weeks, and tumor shrinkage can follow over months of consistent treatment.
That said, a newer medication called cabergoline has largely overtaken bromocriptine as the first-choice treatment for hyperprolactinemia. A meta-analysis of randomized controlled trials found that cabergoline was significantly more effective at normalizing prolactin levels, restoring regular menstrual cycles, and returning ovulation. It also caused fewer side effects, with notably lower rates of nausea and vomiting. Bromocriptine remains a viable option, particularly when cabergoline isn’t available or tolerated, or during pregnancy planning where its longer safety record offers reassurance.
Parkinson’s Disease
In Parkinson’s disease, the brain loses dopamine-producing neurons, leading to tremor, stiffness, and difficulty with movement. Bromocriptine helps by directly stimulating the dopamine receptors that these lost neurons would normally activate. It’s typically used as an add-on to levodopa (the primary Parkinson’s medication) rather than as a standalone treatment.
Research published in JAMA Neurology found that low-dose bromocriptine produced modest but significant improvement when added to levodopa therapy, with the most noticeable benefit in reducing tremor. The sweet spot for effectiveness was between 7.5 and 15 mg daily, with some decline in benefit as doses approached 20 mg. Today, newer dopamine agonists with fewer side effects have largely replaced bromocriptine in Parkinson’s management, but it remains an option in certain clinical situations.
Type 2 Diabetes
A quick-release formulation of bromocriptine is approved specifically for type 2 diabetes. This use might seem surprising for a dopamine-activating drug, but it works through a completely different pathway than its other applications. Taken within two hours of waking, it targets circadian (daily rhythm) signaling in the hypothalamus, the brain region that regulates metabolism. In people with insulin resistance, this signaling is often abnormally elevated, driving up blood sugar, free fatty acids, and triglycerides. Bromocriptine helps reset that drive by boosting dopamine activity and dialing down excessive nervous system stimulation.
The practical result is lower blood sugar after meals, primarily by reducing the liver’s overproduction of glucose. In clinical trials, the quick-release formulation lowered A1c by 0.4 to 0.8 percentage points, whether used alone or alongside other diabetes medications. That’s a moderate improvement, so it’s generally used as one piece of a larger treatment plan rather than a primary therapy.
Acromegaly
Bromocriptine is also used to treat acromegaly, a condition where the pituitary gland overproduces growth hormone, causing enlarged hands, feet, and facial features along with joint pain and other complications. In an early clinical study, doses of 20 mg daily suppressed growth hormone levels in 9 out of 11 patients over several weeks of treatment. While other medications are now preferred for acromegaly, bromocriptine can still play a role, especially in patients who also have elevated prolactin.
A Use That Was Withdrawn
Bromocriptine was once widely prescribed to suppress breast milk production after childbirth. The FDA removed this indication in 1994 after reports of serious complications in postpartum women, including stroke (some fatal), seizures, heart attacks, and severe high blood pressure. It is no longer approved for lactation suppression in the United States, and its use for this purpose is discouraged in most other countries as well.
Common Side Effects
Nausea is the most frequent side effect, affecting roughly 32% of people in clinical trials compared to about 8% on placebo. The good news: for most people, nausea occurs during the initial dose-increase period and resolves within two weeks. Other common side effects include vomiting, dizziness, headache, and diarrhea. Starting at a low dose and increasing gradually helps minimize these effects, and taking the medication with food can also help.
Dizziness from blood pressure drops when standing up (orthostatic hypotension) is another concern, particularly in the first few days. Getting up slowly from sitting or lying down reduces this risk.
Heart Valve Concerns
Because bromocriptine belongs to the ergot-derived dopamine agonist family, questions have been raised about heart valve problems seen with related drugs like pergolide and cabergoline. However, research published in the New England Journal of Medicine found no new cases of valve regurgitation among patients taking bromocriptine. The key difference appears to be that bromocriptine blocks, rather than activates, the specific serotonin receptor on heart valves that causes fibrotic thickening. This makes it a lower-risk option within its drug class for long-term use, though periodic monitoring is still reasonable for patients on high doses over many years.